Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OR2805 in advanced solid tumors
NCT05094804Phase 2Recruiting
- Sponsor
- OncoResponse
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of OR2805 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), leiomyosarcoma (LMS), sponsored by OncoResponse. Started Sep 2021; status: recruiting.
02
Drugs
OR2805
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)melanomahead and neck squamous cell carcinoma (HNSCC)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT05094804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094804.